A homegrown challenger
Eppe’s active ingredient, efpeglenatide, is a long-acting GLP-1 receptor agonist built on Hanmi’s LAPSCOVERY platform and given as a weekly injection. Hanmi filed for approval late last year, and the drug was placed on the regulator’s fast-track review program, putting a launch within reach before year-end.
Hanmi has not announced a final price or dosage structure, but industry estimates suggest about 150,000 won for a four-week supply. That compares with the lowest prices listed on Friday on the price-comparison platform My Doctor: 272,000 won for four weeks of Mounjaro at 2.5 milligrams and 210,000 won for Wegovy at 0.25 milligrams.
A market ruled by two giants
Eppe enters a booming but concentrated field:
- Mounjaro held about 85 percent of Korea’s obesity drug market in August and Wegovy roughly 8 percent, according to BRP Insight.
- The market more than tripled to 819.5 billion won last year from 242.6 billion won in 2024, according to IQVIA.
- Before Mounjaro’s Korean launch in August 2025, Novo Nordisk cut Wegovy’s wholesale prices by roughly 10 to 44 percent, replacing a uniform 372,000 won with dose-based prices from 210,000 to 320,000 won.

















